SnoRNAs in cardiovascular development, function, and disease

Alzbeta Chabronova; Terri L Holmes; Duc M Hoang; Chris Denning; Victoria James; James G W Smith; Mandy J Peffers

doi:10.1016/j.molmed.2024.03.004

SnoRNAs in cardiovascular development, function, and disease

Trends Mol Med. 2024 Mar 23:S1471-4914(24)00059-5. doi: 10.1016/j.molmed.2024.03.004. Online ahead of print.

Authors

Alzbeta Chabronova¹, Terri L Holmes², Duc M Hoang³, Chris Denning³, Victoria James⁴, James G W Smith², Mandy J Peffers⁵

Affiliations

¹ Department of Musculoskeletal Ageing Science, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, L7 8TX, UK. Electronic address: A.Chabronova@liverpool.ac.uk.
² Centre for Metabolic Health, Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, NR4 7UQ, UK.
³ Department of Stem Cell Biology, Biodiscovery Institute, University of Nottingham, University Park, Nottingham, NG7 2RD, UK.
⁴ School of Veterinary Medicine and Science, Biodiscovery Institute, University of Nottingham, University Park, Nottingham, NG7 2RD, UK.
⁵ Department of Musculoskeletal Ageing Science, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, L7 8TX, UK.

PMID: 38523014
DOI: 10.1016/j.molmed.2024.03.004

Abstract

Small nucleolar RNAs (snoRNAs) are emerging as important regulators of cardiovascular (patho)biology. Several roles of snoRNAs have recently been identified in heart development and congenital heart diseases, as well as their dynamic regulation in hypertrophic and dilated cardiomyopathies, coronary heart disease (CHD), myocardial infarction (MI), cardiac fibrosis, and heart failure. Furthermore, reports of changes in vesicular snoRNA expression and altered levels of circulating snoRNAs in response to cardiac stress suggest that snoRNAs also function in cardiac signaling and intercellular communication. In this review, we summarize and discuss key findings and outline the clinical potential of snoRNAs considering current challenges and gaps in the field of cardiovascular diseases (CVDs).

Keywords: biomarker; cardiac fibrosis; cardiomyopathy; exercise; extracellular vesicles; snoRNA.

Publication types

Review